Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
This study is looking at whether monthly injections of hyaluronidase (Hylenex) can help improve stiff and tight fingers (sclerodactyly) in people with systemic sclerosis. Researchers believe that low levels of a natural enzyme called hyaluronidase might contribute to the skin hardening seen in this condition. This study will give hyaluronidase injections into one finger on each hand for 28 weeks. They want to see if this treatment is safe and practical to give, and if it helps with hand movement. They are looking for 10 participants between 18 and 60 years old who have systemic sclerosis and sclerodactyly. The study is currently unclear about its recruitment status.
- Study design
- This is an open-label study, meaning both you and the study team will know you are receiving the treatment. It will include 10 participants.
- What's involved
- You would receive monthly injections of hyaluronidase into one finger on each hand over a 28-week treatment period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be checked for 32 weeks after the start of the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Feasibility Assessment28 weeks
The primary measures of feasibility will be study refusal rate and visit adherence during the treatment period. If the study refusal rate is more than 70% the study will be deemed unfeasible
- Evaluate Safety32 weeks
Will monitor for adverse events and serious adverse events at every 4 week visit. All will be graded using Common Terminology Criteria for Adverse Events